Histamine and Interleukin-2 in Acute Myelogenous Leukemia

References

• Trinchieri G. Biology of natural killer cells. Adv. Immunol 1989; 47: 187–376
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Lotze M. T., Muul L. M. A progress report on the treatment of 157 patients with advanced cancer using lymphokine‐activated killer cells and interleukin‐2 or interleukin‐2 alone. N. Engl. J. Med. 1987; 316: 889–897
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Lotze M. T., Yang J. C., Aebersold P. M. Experience with the use of high‐dose interleukin‐2 in the treatment of 652 cancer patients. Ann. Surg. 1989; 210: 474–485
   PubMed Web of Science ®Google Scholar
• Bukowski R. M., Goodman R., Crawford E. D. A phase II study of high‐dose intermittent interleukin‐2 in metastatic renal cell carcinoma. J. Clin. Oncol. 1989; 7: 477–485
   PubMedGoogle Scholar
• Foa R. Interleukin‐2 in the management of acute leukemia. Br. J. Haematol. 1996; 92: 1–3
   PubMed Web of Science ®Google Scholar
• MacDonald D., Jiang Y. Z., Gordon A. A. Recombinant IL 2 for acute myeloid leukemia in first complete remission: a pilot study. Leuk. Res. 1990; 14: 967–973
   PubMed Web of Science ®Google Scholar
• Shepherd J. D., Jacky E., Grathwohl A., Helbig W., Maranchini D., Zittoun R., Newland A., Prentice A., Selleslag D., Fey M., Cavalli F., Hess U., Bell A., Prentice H. G., Gerhartz H. H., Mertelsman R., Fenaux P., Bosly A., Ferrant A., Gluck S., Michal S., Osterwalder B. Phase II study of subcutaneous rHu IL‐2 in patients with acute myelogenous leukaemia in partial or complete second remission and partial relapse. Br. J. Haematol 1994; S87: 205
   Google Scholar
• Blaise D., Attal A., Pico J. L., Reiffers J., Stoppa A. M., Bellanger C., Molina L., Nedellec G., Vernant J. P., Legros M., Gabus R., Huguel F., Brandely M., Hercend T., Olive D., Maranchini D. Impact of recombinant IL‐2 (rIL‐2) after autologous BMT in 50 patients with CR1 acute leukaemia. Br. J. Haematol 1996; S19: 122
   Google Scholar
• Bergmann L., Heil G., Kolbe K., Lengfelder E., Puzicha E., Martin H., Lohmeyer J., Mitrou P. S., Hoelzer D. Interleukin‐2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukaemia. Leuk. Lymphoma 1995; 6: 271–279
   Web of Science ®Google Scholar
• Brunda M. J., Bellantoni D., Sulich V. In vivo anti‐tumour activity of combinations of interferon alpha and interleukin‐2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int. J. Cancer 1987; 40: 365–341
   PubMed Web of Science ®Google Scholar
• Maekawa R., Kitagawa T., Koizumi K., Sato K., Homma M. Distinct antitumor mechanisms of recombinant interleukin‐2 on recombinant interleukin‐2‐activated killer‐sensitive and ‐resistant murine tumours. J. Biol Response Mod. 1989; 8: 676–690
   PubMedGoogle Scholar
• Mule J. J., Yang J. C., Lafreniere R., Shu S., Rosenberg S. A. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high‐dose recombinant interleukin‐2. J. Immunol 1987; 139: 285–299
   PubMed Web of Science ®Google Scholar
• Lotze M. T., Rosenberg S. A. Interleukin 2 as a pharmacologic reagent. Interleukin‐2, K. A. Smith. Academic Press, San Diego 1988; 237–294
   Google Scholar
• Hellstrand K., Kjellson B., Hermodsson S. Monocyte‐induced down‐modulation of CD16 and CD56 Ag expression on human natural killer cells and its regulation by histamine H2‐receptors. Cell Immunol 1991; 138: 44–54
   PubMed Web of Science ®Google Scholar
• Hellstrand K., Hermodsson S. Cell‐to‐cell mediated inhibition of natural killer cell proliferation by monocytes and its regulation by histamine H2‐receptors. Scand. J. Immunol 1991; 34: 741–752
   PubMed Web of Science ®Google Scholar
• Hellstrand K., Hermodsson S. Monocyte‐medi‐ated suppression of IL‐2‐induced NK‐cell activation: Regulation by serotonin 5‐HT1A receptors. Scand. J. Immunol 1990; 32: 183–192
   PubMed Web of Science ®Google Scholar
• Hellstrand K., Hermodsson S. Synergistic NK cell activation by histamine and interleukin‐2. Int. Arch. Allergy Appl. Immunol 1990; 92: 379–389
   PubMedGoogle Scholar
• Asea A., Hansson M., Czerkinsky C., Hermodsson S., Strannegård Ö., Hellstrand K. Histaminergic regulation of the production of IFN‐γ by human natural killer cells. Clin. Exp. Immunol 1996; 105: 376–382
   PubMed Web of Science ®Google Scholar
• Hellstrand K., Asea A., Hermodsson S. Histaminergic regulation of NK‐cells: role of monocyte‐derived, reactive oxygen metabolites. J. Immunol 1994; 153: 4940–4947
   PubMed Web of Science ®Google Scholar
• Hansson M., Asea A., Ersson U., Hermodsson S., Hellstrand K. Induction of apoptosis in natural killer cells by monocyte‐derived reactive oxygen metabolites. J. Immunol 1996; 156: 42–47
   PubMed Web of Science ®Google Scholar
• Hansson M., Asea A., Hermodsson S., Hellstrand K. Histaminergic regulation of NK‐cells: protection against monocyte‐induced apoptosis. Scand. J. Immunol 1996; 42: 193–196
   Web of Science ®Google Scholar
• Kono K., Salazar‐Onfray F., Petersson M., Hansson J., Masucci G., Wasserman K., Nakazawa T., Anderson P., Kiessling R. Hydrogen peroxide secreted by tumor‐derived macrophages down‐modulates signal‐transducing zeta molecules and inhibits tumor‐specific T‐cell‐and natural killer cell‐mediated cytotoxicity. Eur. J. Immunol 1996; 26: 1308–1313
   PubMed Web of Science ®Google Scholar
• Matsuda M., Petersson M., Lenkei R., Taupin J. L., Magnusson I., Mellstedt H., Anderson P., Kiessling R. Alterations in the signal‐transducing molecules of T‐cells and NK‐cells in colorectal tumor‐infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int. J. Cancer 1995; 61: 765–772
   PubMed Web of Science ®Google Scholar
• Allen C., Hogg N. Elevation of infiltrating mononuclear phagocytes in human colorectal tumors. J. Natl. Cancer Inst. 1987; 78: 465–470
   PubMed Web of Science ®Google Scholar
• Brocker E. B., Zwadlo G., Suter L., Brune M., Sorg C. Infiltration of primary and metastatic melanomas with macrophages of the 25F9‐positive phenotype. Cancer Immunol Immunother. 1987; 25: 81–86
   PubMed Web of Science ®Google Scholar
• Brune M., Hellstrand K. Remission maintenance therapy with histamine and interleukin‐2 in acute myelogenous leukemia. Br. J. Haematol 1996; 92: 620–626
   PubMed Web of Science ®Google Scholar
• Brune M., Hansson M., Mellqvist U. ‐H., Hermodsson S., Hellstrand K. NK‐cell‐mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites. Eur. J. Haematol 1996; 57: 312–319
   PubMed Web of Science ®Google Scholar
• Hellstrand K., Hermodsson S. Histamine H2‐receptor mediated regulation of human natural killer cell cytotoxicity. J. Immunol 1986; 137: 656–660
   PubMed Web of Science ®Google Scholar
• Hellstrand K., Asea A., Hermodsson S. Role of histamine in natural killer cell mediated resistance against tumor cells. J. Immunol 1990; 145: 4365–4370
   PubMed Web of Science ®Google Scholar
• Asea A., Hermodsson S., Hellstrand K. Histaminergic regulation of natural killer‐cell‐mediated clearance of tumor cells in mice. Scand. J. Immunol 1996; 43: 9–15
   PubMed Web of Science ®Google Scholar
• Hellstrand K., Naredi P., Lindnér P., Lundholm K., Hermodsson S., Rudenstam C. ‐M., Azstély M., Hafström L. ‐O. Histamine in immunotherapy of advanced melanoma. A pilot study. Cancer Immunol. Immunother. 1994; 39: 416–419
   PubMed Web of Science ®Google Scholar
• Archimbaud E., Bailly M., Doré J. F. Inducibility of lymphokine‐activated killer (LAK) cells in patients with acute myelogenous leukemia in complete remission and its clinical relevance. Br. J. Haematol 1991; 77: 328–234
   PubMed Web of Science ®Google Scholar
• Lauria F., Raspadori D., Rondelli D., Ventura M. A., Foa R. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lym‐phokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival. Leukemia 1994; 8: 724–728
   PubMed Web of Science ®Google Scholar
• Maraninchi D., Blaise D., Viens P., Brandely M., Olive D., Lopez M., Sainty D., Marit G., Stoppa A. M., Reiffers J. High‐dose recombinant interleukin‐2 and acute myeloid leukemias in relapse. Blood. 1991; 78: 2182–2187
   PubMed Web of Science ®Google Scholar
• Meloni G., Foa R., Vignetti M., Guarini A., Fenu S., Tosti S., Tos A. G., Mandelli F. Interleukin‐2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 1994; 84: 2158–2163
   PubMed Web of Science ®Google Scholar
• Cassileth P. A., Lynch E., Hines J. D., Oken M. M., Mazza J. J., Bennett J. M., McGlave P. B., Edelstein M., Harrington D. P., O'Connell M. J. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992; 79: 1924–1930
   PubMed Web of Science ®Google Scholar
• Vogler W. R. Strategies in the treatment of acute myelogenous leukemia. Leuk. Res. 1992; 16: 1143–1153
   PubMed Web of Science ®Google Scholar
• Mastrianni D. M., Tung N. M., Tenen D. G. Acute myelogenous leukemia: current treatment and future directions. Am. J. Med. 1992; 92: 286–295
   PubMed Web of Science ®Google Scholar
• Swansbury G. J., Lawler S. D., Alimena G., Arthur D., Berger R., Van den Berghe H., Bloomfield C. D., de la Chappelle A., Dewald G., Garson O. M. Long‐term survival in acute myelogenous leukemia: a second follow‐up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet. Cytogenet. 1994; 73: 1–7
   PubMed Web of Science ®Google Scholar
• Thalhammer F., Geissler K., Jager U., Kyrle P. A., Pabinger I., Mitterbauer M., Gisslinger H., Knobl P., Laczika K., Schneider B., Haas O. A., Lechner K. Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single‐center study. Ann. Hematol. 1996; 72: 216–222
   PubMed Web of Science ®Google Scholar